“We are extremely delighted to have such a seasoned leader in the diagnostics field join Althea Diagnostics,” stated Co-President and Co-CEO of Althea Technologies, Dr. François Ferré. “David brings to the new company not only a demonstrated ability to translate diverse technologies into innovative products, but also a track record of making those products successful worldwide.”

Mr. Macdonald served as President and COO of Nichols Institute Diagnostics, a division of Quest Diagnostics, as President and CEO of Progeny Systems and Medical Electronic Systems, in operational roles at Nanogen, Behring Diagnostics and Nova Biomedical, and most recently as President and Chief Executive Officer at Nanomix.

“I am pleased to lead the exciting developments at Althea Diagnostics and look forward to being part of a team establishing a leadership position in cancer diagnostics,” added Mr. Macdonald.

About Althea Diagnostics, Incorporated

Althea Diagnostics is focused on providing genetic testing services and diagnostic products related to oncology applications. Althea Diagnostics’ goal is to cure cancer by reducing the time, risk, and cost of cancer drug development and bringing cancer diagnostics into widespread clinical use. For more information, visit www.altheadx.com.